Risks of Neoadjuvant Chemotherapy and Radiation Therapy

Thoracic Surgery Clinics

Volumn 18, Issue 1, 2008, Pages 71-80

  Stamatis, Georgios ^a  

^a RUHRLANDKLINIK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN;

ADJUVANT CHEMOTHERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ATELECTASIS; BLEEDING; BLOOD TRANSFUSION; BRONCHOPLEURAL FISTULA; CLINICAL TRIAL; EMPYEMA; HEART ARRHYTHMIA; HEART FUNCTION TEST; HOSPITALIZATION; HUMAN; LUNG EDEMA; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MORBIDITY; MORTALITY; PERFORMANCE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; PNEUMONECTOMY; RADIOTHERAPY, ADJUVANT;

EID: 38849196945     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2007.11.004     Document Type: Review

References (80)

1. Levi F., Lucchini F., Negri E., et al. Cancer mortality in Europe 1995-1999, and an overview of trends since 1960. Int J Cancer 1105 (2004) 155-169
2. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 1 (2004) 8-29
3. Ginsberg R.J., Vokes E.E., and Raben A. Non-small cell lung cancer. In: De Vita Jr. V.T., Hellmann S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 5th edition (1997), Lippincott, Philadelphia 858-911
4. Fabrice A., Grunenwald D., Pignon J.P., et al. Survival of patients with resected N2 non small cell lung cancer (NSCLC): heterogeneity of prognosis and evidence for a subclassification. (abstract). Proc Am Soc Clin Oncol 18 (1999) 1802
5. Van Raemdonck D.E., Schneider A., and GinsbergRJ. Surgical treatment for higher stage non-small cell lung cancer. Ann Thorac Surg 54 (1992) 999-1013
6. Mathisen D.J., and Grillo H.C. Carinal resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg 102 (1988) 16-23
7. Johnson D.H., Turrisi A.T., and Pass H.J. Combined modality treatment for locally advanced non-small cell lung cancer. In: Pass H.J., Mitchell J., Johnson D.H., and Turrisi A.T. (Eds). Lung cancer: principles and practice (1996), Lippincott, Philadelphia 863-873
8. Albain K.S., Rush V., Crowley J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: major mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13 (1995) 1880-1892
9. Choi N., Carey R., Daly W., et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 15 (1997) 712-722
10. Eberhardt W., Wilke H., Stamatis G., et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial. J Clin Oncol 16 (1998) 622-634
11. Thomas M., Rübe C., Semik M., et al. Chemotherapy and subsequent twice-daily chemoradiation before surgery in stage III non-small cell lung cancer: impact of tumor regression on survival. J Clin Oncol 17 (1999) 1185-1193
12. Roth J.A., Fossela F.V., Komaki R., et al. A randomised trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86 (1994) 673-680
13. Rossell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330 (1994) 153-158
14. Depierre A., Milleron B., Moro-Sibilot D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II and IIIA non-small cell lung cancer. J Clin Oncol 20 (2002) 247-253
15. Fowler W.C., Langer C.J., Curran W.J., et al. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 55 (1993) 986-989
16. Roberts J.R., Eustis C., Devore R., et al. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 72 (2001) 885-888
17. Martin J., Ginsberg R.J., Abolhoda A., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy. Ann Thorac Surg 72 (2001) 1149-1154
18. Albain K.S., Scott C.B., Rusch V.W., et al. Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA(N2) non-small cell lung cancer (NSCLC): first outcome analysis of North American Intergroup trial 0139 (RTOG 93-09). Lung Cancer 41 Suppl 2 (2003) S4
19. Van Meerbeeck J.P., van Schil P.E., Seuan S., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA N2 non-small cell lung cancer. J Natl Cancer Inst 99 (2007) 442-450
20. Bernard A., Deschamps C., Allen M.S., et al. Peumonectomy for malignant disease: factors affecting early morbidity and mortality. J Thorac Cardiovasc Surg 121 (2001) 1076-1082
21. Wada H., Nakamura T., Nakamoto K., et al. Thirty-day operative mortality for thoracotomy in lung cancer. Thorac Cardiovasc Surg 115 (1998) 70-73
22. Licker M., Spiliopoulos A., Frey J.G., et al. Risk factors for early mortality and major complications following pneumonectomy for non-small cell carcinoma of the lung. Chest 121 (2002) 1890-1897
23. Martini N., Kris M.G., Flehinger B.J., et al. Preoperative chemotherapy for stage IIIA (N2): the Sloan-Kattering experience with 136 patients. Ann Thorac Surg 55 (1993) 1365-1374
24. Sugarbaker D.J., Herndorn J., Kohman L.J., et al. Results of cancer and leukaemia group B protocol 8935: a multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg 109 (1995) 473-485
25. Doddoli C., Thomas P., Thirion X., et al. Postoperative complications in relation with induction therapy for lung cancer. Eur J Cardiothorac Surg 20 (2001) 385-390
26. Siegenthaler M.P., Pisters K.M., Merriman K.W., et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 71 (2001) 1105-1112
27. Perrot E., Guibert B., Mulsant P., et al. Preoperative chemotherapy does not increase complications after non-small cell lung cancer resection. Ann Thorac Surg 80 (2005) 423-427
28. Pezzetta E., Stupp R., Zouhair A., et al. Comparison of neoadjuvant cisplatin-based chemotherapy versus chemoradiotherapy followed by resection for stage III(N2) NSCLC. Eur J Cardiothorac Surg 27 (2005) 1092-1098
29. Van Schil P., van Meerbeeck J., Kramer G., et al. Morbidity and mortality in surgery arm of EORTC 08941 trial. Eur Respir J 26 (2005) 192-197
30. Brunelli A., Xiumé F., Refai M.A., et al. Gemcitabine-cisplatin chemotherapy before lung resection: a case-matched analysis of early outcome. Ann Thorac Surg 81 (2006) 1963-1968
31. Deutsch M., Crawford J., Leopold K., et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer 74 (1994) 1243-1252
32. Grunenwald D.H., André F., Le Péchoux C., et al. Benefit of surgery after chemoradiortherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 122 (2001) 796-802
33. Semik M., Riesenbeck D., Linder A., et al. Preoperative chemotherapy with and without additional radiochemotherapy: benefit and risk for surgery of stage III non-small cell lung cancer. Eur J Cardiothorac Surg 26 (2004) 1205-1210
34. Fujita S., Katakami N., Takahashi Y., et al. Postoperative complications after induction chemoradiotherapy in patients with non small cell lung cancer. Eur J Cardiothorac Surg 29 (2006) 896-901
35. Machtay M., Lee J.H., Stevenson J.P., et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long term results and associations with pathologic response. J Thorac Cardiovasc Surg 127 (2004) 108-113
36. Gauler T., Eberhardt W., Le Pechoux C., et al. Multicenter German/French phase II trial of induction CTX followed by concurrent CTX/RTX+/-surgery in locally for advanced inoperable non-small cell lung cancer stages IIIA (N2) and IIIB-mature results of a novel induction CTX regimen. J Cancer Res Clin Oncol 130 (2004) S72
37. Friedel G., Budach W., Sprengler W., et al. Phase II trial on neo-adjuvant chemoradiation with paclitaxel/carboplatin in stage III NSCLC. J Cancer Res Clin Oncol 130 (2004) S72
38. Venouta F., Anile M., Diso D., et al. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg 31 (2007) 714-718
39. Mansour Z., Kochetkova E.A., Ducrocq X., et al. Induction chemotherapy does not increase the operative risk of pneumonectomy. Eur J Cardiothorac Surg 31 (2007) 181-185
40. Takeda S., Maeda H., Okada T., et al. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur J Cardiothoracic Surg 30 (2006) 184-189
41. Gilligan D., Nicolson M., Smith I., et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 369 (2007) 1929-1937
42. Yokomise H., Gotoh M., Okamoto T., et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg 133 (2007) 1179-1185
43. Sonnett J.R., Krasna M.J., Suntharalingam M., et al. Safe pulmonary resection after chemotherapy and high-dose thoracic radiation. Ann Thorac Surg 68 (1999) 316-320
44. Daly B.D.T., Fernando H.C., Ketchedjian A., et al. Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg 82 (2006) 227-231
45. Cerfolio R.J., Bryant A.S., Spencer S., et al. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg 80 (2005) 1224-1230
46. Shaikh A.Y., Haraf D.J., Salama J.K., et al. Chemotherapy and high dose radiotherapy followed by resection in locally advanced nonsmall cell lung cancer. Am J Clin Oncol 30 (2007) 258-263
47. Stamatis G., Djuric D., Eberhardt W., et al. Postoperative morbidity and mortality after induction chemotherapy for locally advanced lung cancer: an analysis of 350 operated patients. Eur J Cardiothorac Surg 22 (2002) 292-297
48. Brouchet L., Bauvin E., Marcheix B., et al. Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer. J Thorac Oncol 2 (2007) 626-631
49. Cerfolio R.J., and Bryant A.S. Survival and outcomes of pulmonary resection for non-small cell lung cancer in the elderly: a nested case-control study. Ann Thorac Surg 82 (2006) 424-429
50. Harpole D.H., Liptay M.J., DeCamp M.M., et al. Prospective analysis of pneumonectomy: risk factors fro major morbidity and cardiac dysrhythmias. Ann Thorac Surg 61 (1996) 977-982
51. Cerfolio R.J., Bryant A.S., Scott E., et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 130 (2006) 1796-1802
52. Macchiarini P., Chapelier A.R., Monet I., et al. Extended operations after induction stage IIIB (T4) non-small cell lung cancer. Ann Thorac Surg 57 (1994) 966-973
53. Rice T.W., Adelstein D.J., Koka A., et al. Accelerated induction therapy and resection for poor prognosis Stage III non-small cell lung cancer. Ann Thorac Surg 60 (1995) 586-592
54. DeCamp M.M., Rice T.W., Adelstein D.J., et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac Cardiovasc Surg 121 (2003) 17-27
55. Stamatis G., Eberhardt W., and Pöttgen C. Surgery after multimodality treatment for non-small cell lung cancer. Lung Cancer 45 Suppl 2 (2004) 107-112
56. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy(CT/RT) vs. CT/RT followed by surgical resection for stage IIIA(N2) non-small cell lung cancer (NSCL): outcomes update of North American Intergroup 0139 (RTOG 9309). ASCO 2005 Abstract No: 7014.
57. Azad S.C., Groh J., Beyer A., et al. Continuous peridural analgesia vs. patient-controlled intravenous analgesia for pain therapy after thoracotomy. Anaesthesist 49 (2000) 9-17
58. Peeters-Asdourian G., and Gupta S. Choices in pain management following thoracotomy. Chest 115 Suppl (1999) 1228-1248
59. Leo F., Solli P., Spaggiari, et al. Respiratory function changes after chemotherapy: an additional risk factor for postoperative respiratory complications. Ann Thorac Surg 77 (2004) 260-265
60. Brunelli A., Refai M., Salati M., et al. Predicted versus observed FEV1 and DLCO after major lung resection: a prospective evaluation at different postoperative periods. Ann Thorac Surg 83 (2007) 1134-1139
61. Takeda S., Funakoshi Y., Kadota Y., et al. Fall in diffusing capacity associated with induction therapy for lung cancer: a preditor of postoperative complications?. Ann Thorac Surg 82 (2006) 232-236
62. Abou-Jawde R.M., Mekhail T., Adelstein D.J., et al. Impact of induction chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer. Chest 128 (2005) 250-255
63. Videtic G.M., Stitt L.W., Ash R.B., et al. Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer treated with concurrent chemoradiation. Lung Cancer 43 (2004) 159-166
64. Harpole D.H., DeCamp M.M., Daley J., et al. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. J Thorac Cardiovasc Surg 117 (1999) 969-979
65. Ferguson M.K., Reeder L.B., and Mick R. Optimizing selection of patients for major lung resection. J Thorac Cardiovasc Surg 61 (1996) 977-982
66. Wang J., Olak J., Ultmann R.E., et al. Assessment of pulmonary complications after lung resection. Ann Thorac Surg 67 (1999) 1444-1447
67. Kohman L.J., Meyer J.A., Ikins P.M., et al. Random versus predictable risks of mortality after thoracotomy for lung cancer. J Thorac Cardiovasc Surg 91 (1986) 551-554
68. Doddoli C., Barlesi F., Trousse D., et al. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 130 (2005) 416-425
69. Deslauriers J. Invited commentary. Ann Thorac Surg 72 (2001) 1154
70. Deslauriers J., Grégoire J., Jacques L.F., et al. Sleeve lobectomy vs pneumonectomy for lung cancer: a comparative analysis of survival and sites of recurrences. Ann Thorac Surg 77 (2004) 1152-1156
71. Wahi R., McMurtrey M.J., De Caro L.F., et al. Determinants of perioperative morbidity and mortality after pneumonectomy. Ann Thorac Surg 48 (1989) 33-37
72. Au J., elOakley R., and Cameron E.W. Pneumonectomy for bronchogenic carcinoma in the elderly. Eur J Cardiovasc Surg 8 (1994) 247-250
73. Darling G.E., Abdurahman A., Yi Q.L., et al. Risk of a right pneumonectomy: role of bronchopleural fistula. Ann Thorac Surg 79 (2005) 433-437
74. Liptay M.J., and Frey W.A. Complications from induction regimens for thoracic malignancies. Perioperative considerations. Chest Surg Clin N Am 9 (1999) 79-95
75. Deschamps C., Bernard A., Nichols F.C., et al. Empyema and bronchopleural fistula after pneumonectomy: factors affecting incidence. Ann Thorac Surg 72 (2001) 243-248
76. Levashev Y.N., Akopov A.L., and Mosin I.V. The possibilities of greater omentum usage in thoracic surgery. Eur J Cardiothorac Surg 15 (1999) 465-468
77. Rendina A.E., Venuta F., De Giacomo T., et al. Safety and efficacy of bronchovascular reconstruction after induction chemotherapy for lung cancer. J Thorac Cardiovasc Surg 114 (1997) 830-837
78. Burnfeind W.R., D'Amico T.A., Toloza E.M., et al. Low morbidity and mortality for bronchoplastic procedures with and without induction treatment. Ann Thorac Surg 80 (2005) 418-422
79. Yamamoto R., Tada H., Kishi A., et al. Effect of preoperative chemotherapy and radiation therapy on human bronchial blood flow. J Thorac Cardiovasc Surg 119 (2000) 939-945
80. Port J.L., Korst R.J., Lee P.C., et al. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg 79 (2005) 1686-1690